GGrantIndex
← Leaderboards

Rick T Dobrowsky

University Of Kansas Lawrence

$8,170,709
Attributed
$9,570,682
Total exposure
9
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $774.2K · FY200622
$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22

Funding mix

By agency

NIH$9,570,682 · 9

By mechanism

R01$8,140,829 · 6
R33$751,688 · 1
R61$387,165 · 1
R21$291,000 · 1

Top collaborators

Most similar at University Of Kansas Lawrence

Same institution · by research overlap

Others in their field

Top investigators on “Diabetic

Research focus

DiabeticPeripheral Nervous System DiseasesDiabetes MellitusProteinsStressComplexNerve DegenerationMetabolicDiabetic NeuropathiesHyperglycemiaNeuropathyPhysiologicalSeriesNeuronsGlucoseNerveBiochemicalSchwann CellsIn VivoPeripheral NervesDemyelinationsApoptosisEtiologyResponse

Grant awards (35)

A Novel Pharmacologic Approach to Treat CMT1X$371,450
R33 · FY2022 · NS · contact PI
A Novel Pharmacologic Approach to Treat CMT1X$380,238
R33 · FY2021 · NS · contact PI
A Novel Pharmacologic Approach to Treat CMT1X$387,165
R61 · FY2020 · NS · contact PI
Chaperone therapeutics for the treatment of DPN$387,083
R01 · FY2020 · NS
Chaperone therapeutics for the treatment of DPN$387,083
R01 · FY2019 · NS
Chaperone therapeutics for the treatment of DPN$384,583
R01 · FY2018 · NS
Chaperone therapeutics for the treatment of DPN$352,351
R01 · FY2017 · NS
Chaperone therapeutics for the treatment of DPN$32,232
R01 · FY2017 · NS
Chaperones in Diabetic Peripheral Neuropathy$326,250
R01 · FY2016 · DK · contact PI
Chaperones in Diabetic Peripheral Neuropathy$326,250
R01 · FY2015 · DK · contact PI
Chaperone therapeutics for the treatment of DPN$317,274
R01 · FY2015 · NS
Chaperones in Diabetic Peripheral Neuropathy$325,888
R01 · FY2014 · DK · contact PI
Chaperone therapeutics for the treatment of DPN$314,419
R01 · FY2014 · NS
Chaperones in Diabetic Peripheral Neuropathy$324,800
R01 · FY2013 · DK · contact PI
Chaperone therapeutics for the treatment of DPN$306,763
R01 · FY2013 · NS
Chaperone therapeutics for the treatment of DPN$318,158
R01 · FY2012 · NS
Caveolin-1 and Altered Neuregulinism in Diabetic Neuropathy$307,701
R01 · FY2012 · NS · contact PI
Caveolin-1 and Altered Neuregulinism in Diabetic Neuropathy$307,881
R01 · FY2011 · NS · contact PI
Caveolin-1 and Altered Neuregulinism in Diabetic Neuropathy$313,062
R01 · FY2010 · NS · contact PI
Oxidative Stress and the Mitochondrial Proteome in Diabetic Neuropathy$329,428
R01 · FY2009 · DK · contact PI
Caveolin-1 and Altered Neuregulinism in Diabetic Neuropathy$316,783
R01 · FY2009 · NS · contact PI
Oxidative Stress and the Mitochondrial Proteome in Diabetic Neuropathy$369,204
R01 · FY2008 · DK · contact PI
Caveolin-1 and Altered Neuregulinism in Diabetic Neuropathy$326,066
R01 · FY2008 · NS · contact PI
Oxidative Stress and the Mitochondrial Proteome in Diabetic Neuropathy$336,484
R01 · FY2007 · DK · contact PI
Oxidative Stress and the Mitochondrial Proteome in Diabetic Neuropathy$39,381
R01 · FY2007 · DK · contact PI
Oxidative Stress and the Mitochondrial Proteome in Diabetic Neuropathy$346,987
R01 · FY2006 · DK · contact PI
REGULATION OF P75NTR SIGNALING IN CAVEOLAE$138,265
R01 · FY2003 · NS
MECHANISMS OF NEUROTROPHIN RECEPTOR CROSSTALK$163,411
R01 · FY2002 · NS
REGULATION OF P75NTR SIGNALING IN CAVEOLAE$134,427
R01 · FY2002 · NS
REGULATION OF P75NTR SIGNALING IN CAVEOLAE$168,862
R01 · FY2001 · NS
MECHANISMS OF NEUROTROPHIN RECEPTOR CROSSTALK$158,711
R01 · FY2001 · NS
ROLE OF CAVEOLIN IN SCHWANN CELL SIGNAL TRANSDUCTION$145,500
R21 · FY2001 · DK
MECHANISMS OF NEUROTROPHIN RECEPTOR CROSSTALK$154,104
R01 · FY2000 · NS
ROLE OF CAVEOLIN IN SCHWANN CELL SIGNAL TRANSDUCTION$145,500
R21 · FY2000 · DK
REGULATION OF P75NTR SIGNALING IN CAVEOLAE$126,938
R01 · FY2000 · NS